SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Advanced Viral Research CP (ADVR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael who wrote (615)8/15/1996 4:54:00 PM
From: Wayne Delfino   of 2281
 
My point was this: I assume that to be published in the Journal of Investigative Medicine (JIM), Dr. Hirschman's paper is well-structured and thoroughly researched. I also assume that the paper had been read and re-read by the journal's prestigious editorial board before being accepted for publication. I further assume that neither the journal nor Dr. Hirschman want to be embarrassed by the intense scientific scrutiny that is certain to follow a paper indicating that Reticulose has been found to have inhibitory effects on HIV and other viral diseases. It is for this reason that I asked: would JIM publish a paper with results it does not believe will be verified? Perhaps. Certainly the journal realizes that Dr. Hirschman's research is certain to create lively scientific controversy. But I would bet that Dr. Hirschman had convinced JIM that he is fully prepared to enter the fray.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News